Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

This AJMC^® Profiles in Care provides an in-depth look into the results of the innovative outcomes-based agreement between Boehringer Ingelheim and Highmark Inc that focused on total cost of care for patients with type 2 diabetes and cardiovascular disease. An overview of the results, as well as valuable insights from experts from Boehringer Ingelheim and Highmark, are included.

Download PDF: Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

Related Content

Why CGM Access and Diabetes Amputations Are Part of the Same Systemic Problem: Alyson K. Myers, MD

Culturally Tailored Diabetes Care Can Improve Outcomes and Reduce Costs: Alyson K. Myers, MD

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

COVID Postexposure Prophylaxis Expands Prevention Toolkit: Noah Greenspan, DPT, PT

AI Reshaping Diabetes Care From Nutrition to Clinical Decisions